Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus ErythematosusCitation formats

  • External authors:
  • Megan Rutter
  • Peter Lanyon
  • Raj Sandhu
  • Rebecca Batten
  • Rebecca Garner
  • Jayne Little
  • Nehal Narayan
  • Nicola Erb
  • Bridget Griffiths
  • Hannah Guest
  • Elizabeth Macphie
  • Jon Packham
  • Chris Hiley
  • Karen Obrenovic
  • Ali Rivett
  • Caroline Gordon
  • Fiona A Pearce

Standard

Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus Erythematosus. / Rutter, Megan; Lanyon, Peter; Sandhu, Raj; Batten, Rebecca; Garner, Rebecca ; Little, Jayne; Narayan, Nehal; Sharp, Charlotte; Bruce, Ian; Erb, Nicola; Griffiths, Bridget; Guest, Hannah; Macphie, Elizabeth; Packham, Jon; Hiley, Chris; Obrenovic, Karen; Rivett, Ali; Gordon, Caroline; Pearce, Fiona A .

In: Rheumatology (Print), Vol. 60, No. 3, 02.03.2021, p. 1474 – 1479 .

Research output: Contribution to journalArticlepeer-review

Harvard

Rutter, M, Lanyon, P, Sandhu, R, Batten, R, Garner, R, Little, J, Narayan, N, Sharp, C, Bruce, I, Erb, N, Griffiths, B, Guest, H, Macphie, E, Packham, J, Hiley, C, Obrenovic, K, Rivett, A, Gordon, C & Pearce, FA 2021, 'Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus Erythematosus', Rheumatology (Print), vol. 60, no. 3, pp. 1474 – 1479 . https://doi.org/10.1093/rheumatology/keaa620

APA

Rutter, M., Lanyon, P., Sandhu, R., Batten, R., Garner, R., Little, J., Narayan, N., Sharp, C., Bruce, I., Erb, N., Griffiths, B., Guest, H., Macphie, E., Packham, J., Hiley, C., Obrenovic, K., Rivett, A., Gordon, C., & Pearce, F. A. (2021). Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus Erythematosus. Rheumatology (Print), 60(3), 1474 – 1479 . https://doi.org/10.1093/rheumatology/keaa620

Vancouver

Author

Rutter, Megan ; Lanyon, Peter ; Sandhu, Raj ; Batten, Rebecca ; Garner, Rebecca ; Little, Jayne ; Narayan, Nehal ; Sharp, Charlotte ; Bruce, Ian ; Erb, Nicola ; Griffiths, Bridget ; Guest, Hannah ; Macphie, Elizabeth ; Packham, Jon ; Hiley, Chris ; Obrenovic, Karen ; Rivett, Ali ; Gordon, Caroline ; Pearce, Fiona A . / Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus Erythematosus. In: Rheumatology (Print). 2021 ; Vol. 60, No. 3. pp. 1474 – 1479 .

Bibtex

@article{3fd913fdc236429b80e0ffe8c390da22,
title = "Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus Erythematosus",
abstract = "OBJECTIVES: We aimed to estimate what proportion of people with SLE attending UK rheumatology clinics would be categorized as being at high risk from coronavirus disease 2019 (COVID-19) and therefore asked to shield, and explore what implications this has for rheumatology clinical practice.METHODS: We used data from the British Society for Rheumatology multicentre audit of SLE, which included a large, representative cross-sectional sample of patients attending UK Rheumatology clinics with SLE. We calculated who would receive shielding advice using the British Society for Rheumatology's risk stratification guidance and accompanying scoring grid, and assessed whether ethnicity and history of nephritis were over-represented in the shielding group.RESULTS: The audit included 1003 patients from 51 centres across all 4 nations of the UK. Overall 344 (34.3%) patients had a shielding score ≥3 and would have been advised to shield. People with previous or current LN were 2.6 (1.9-3.4) times more likely to be in the shielding group than people with no previous LN (P < 0.001). Ethnicity was not evenly distributed between the groups (chi-squared P < 0.001). Compared with White people, people of Black ethnicity were 1.9 (1.3-2.8) and Asian 1.9 (1.3-2.7) times more likely to be in the shielding group. Increased risk persisted after controlling for LN.CONCLUSION: Our study demonstrates the large number of people with SLE who are likely to be shielding. Implications for clinical practice include considering communication across language and cultural differences, and ways to conduct renal assessment including urinalysis, during telephone and video consultations for patients who are shielding.",
keywords = "Adult, COVID-19/prevention & control, Cross-Sectional Studies, Female, Humans, Lupus Erythematosus, Systemic/therapy, Lupus Nephritis/therapy, Male, Medical Audit, Middle Aged, Patient Acceptance of Health Care/statistics & numerical data, Practice Patterns, Physicians'/statistics & numerical data, Quarantine/statistics & numerical data, Regression Analysis, Rheumatology/statistics & numerical data, SARS-CoV-2, Telemedicine/statistics & numerical data, United Kingdom/epidemiology",
author = "Megan Rutter and Peter Lanyon and Raj Sandhu and Rebecca Batten and Rebecca Garner and Jayne Little and Nehal Narayan and Charlotte Sharp and Ian Bruce and Nicola Erb and Bridget Griffiths and Hannah Guest and Elizabeth Macphie and Jon Packham and Chris Hiley and Karen Obrenovic and Ali Rivett and Caroline Gordon and Pearce, {Fiona A}",
note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2021",
month = mar,
day = "2",
doi = "10.1093/rheumatology/keaa620",
language = "English",
volume = "60",
pages = "1474 – 1479 ",
journal = "Rheumatology (Print)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus Erythematosus

AU - Rutter, Megan

AU - Lanyon, Peter

AU - Sandhu, Raj

AU - Batten, Rebecca

AU - Garner, Rebecca

AU - Little, Jayne

AU - Narayan, Nehal

AU - Sharp, Charlotte

AU - Bruce, Ian

AU - Erb, Nicola

AU - Griffiths, Bridget

AU - Guest, Hannah

AU - Macphie, Elizabeth

AU - Packham, Jon

AU - Hiley, Chris

AU - Obrenovic, Karen

AU - Rivett, Ali

AU - Gordon, Caroline

AU - Pearce, Fiona A

N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2021/3/2

Y1 - 2021/3/2

N2 - OBJECTIVES: We aimed to estimate what proportion of people with SLE attending UK rheumatology clinics would be categorized as being at high risk from coronavirus disease 2019 (COVID-19) and therefore asked to shield, and explore what implications this has for rheumatology clinical practice.METHODS: We used data from the British Society for Rheumatology multicentre audit of SLE, which included a large, representative cross-sectional sample of patients attending UK Rheumatology clinics with SLE. We calculated who would receive shielding advice using the British Society for Rheumatology's risk stratification guidance and accompanying scoring grid, and assessed whether ethnicity and history of nephritis were over-represented in the shielding group.RESULTS: The audit included 1003 patients from 51 centres across all 4 nations of the UK. Overall 344 (34.3%) patients had a shielding score ≥3 and would have been advised to shield. People with previous or current LN were 2.6 (1.9-3.4) times more likely to be in the shielding group than people with no previous LN (P < 0.001). Ethnicity was not evenly distributed between the groups (chi-squared P < 0.001). Compared with White people, people of Black ethnicity were 1.9 (1.3-2.8) and Asian 1.9 (1.3-2.7) times more likely to be in the shielding group. Increased risk persisted after controlling for LN.CONCLUSION: Our study demonstrates the large number of people with SLE who are likely to be shielding. Implications for clinical practice include considering communication across language and cultural differences, and ways to conduct renal assessment including urinalysis, during telephone and video consultations for patients who are shielding.

AB - OBJECTIVES: We aimed to estimate what proportion of people with SLE attending UK rheumatology clinics would be categorized as being at high risk from coronavirus disease 2019 (COVID-19) and therefore asked to shield, and explore what implications this has for rheumatology clinical practice.METHODS: We used data from the British Society for Rheumatology multicentre audit of SLE, which included a large, representative cross-sectional sample of patients attending UK Rheumatology clinics with SLE. We calculated who would receive shielding advice using the British Society for Rheumatology's risk stratification guidance and accompanying scoring grid, and assessed whether ethnicity and history of nephritis were over-represented in the shielding group.RESULTS: The audit included 1003 patients from 51 centres across all 4 nations of the UK. Overall 344 (34.3%) patients had a shielding score ≥3 and would have been advised to shield. People with previous or current LN were 2.6 (1.9-3.4) times more likely to be in the shielding group than people with no previous LN (P < 0.001). Ethnicity was not evenly distributed between the groups (chi-squared P < 0.001). Compared with White people, people of Black ethnicity were 1.9 (1.3-2.8) and Asian 1.9 (1.3-2.7) times more likely to be in the shielding group. Increased risk persisted after controlling for LN.CONCLUSION: Our study demonstrates the large number of people with SLE who are likely to be shielding. Implications for clinical practice include considering communication across language and cultural differences, and ways to conduct renal assessment including urinalysis, during telephone and video consultations for patients who are shielding.

KW - Adult

KW - COVID-19/prevention & control

KW - Cross-Sectional Studies

KW - Female

KW - Humans

KW - Lupus Erythematosus, Systemic/therapy

KW - Lupus Nephritis/therapy

KW - Male

KW - Medical Audit

KW - Middle Aged

KW - Patient Acceptance of Health Care/statistics & numerical data

KW - Practice Patterns, Physicians'/statistics & numerical data

KW - Quarantine/statistics & numerical data

KW - Regression Analysis

KW - Rheumatology/statistics & numerical data

KW - SARS-CoV-2

KW - Telemedicine/statistics & numerical data

KW - United Kingdom/epidemiology

U2 - 10.1093/rheumatology/keaa620

DO - 10.1093/rheumatology/keaa620

M3 - Article

C2 - 33677595

VL - 60

SP - 1474

EP - 1479

JO - Rheumatology (Print)

JF - Rheumatology (Print)

SN - 1462-0324

IS - 3

ER -